• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

    5/4/23 7:30:00 AM ET
    $SELB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SELB alert in real time by email

    - Company to implement capital prioritization initiative, extending cash runway to 2H-2025 -

    - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 -

    - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout; BLA filing expected in 1H 2024 -

    - Selecta to host conference call today at 8:30 AM ET -

    WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

    The Company also announced a program prioritization and capital allocation strategy that is expected to extend its cash runway into the second half of 2025.

    "As the only immune tolerance platform with positive Phase 3 data, we firmly believe in the potential of our pipeline of candidates powered by our ImmTOR technology," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. "As we continue to navigate the current market environment, we have undertaken the strategic decision to focus our resources in the areas where we believe we have the highest potential to succeed in delivering meaningful therapies to the patients we aim to serve. In the near term, we look forward to continuing to work with our partner, Sobi®, to advance SEL-212 (ImmTOR in combination with pegadricase) toward a Biologics License Application (BLA), which we continue to expect in the first half of 2024, while also advancing our ImmTOR-IL combination for diseases of the liver."

    Strategic Initiative Overview

    Following a comprehensive review of its portfolio and capital resources, Selecta, in consultation with the Company's Board of Directors, plans to streamline operations and prioritize investments in select programs. As part of this initiative, the Company plans to:

    • Advance SEL-212 in Patients with Chronic Refractory Gout in Partnership with Sobi. In March 2023, Selecta and its SEL-212 development partner, Sobi, reported positive Phase 3 data from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials. Both trials met their primary endpoint, and SEL-212 was observed to be safe and well-tolerated. A BLA submission remains on track for the first half of 2024. In June 2020, Sobi licensed SEL-212 from Selecta and is responsible for development, regulatory, and commercial activities in all markets outside of China.
    • Prioritize Development of the Combination of ImmTOR and Company's Proprietary Treg-Selective IL-2 (ImmTOR-IL). The combination of ImmTOR and IL-2 (ImmTOR-IL) represents an evolution of Selecta's precision immune tolerance platform. The Company remains on track to initiate Investigational New Drug (IND)-enabling studies in 2023, while also exploring multiple autoimmune indications that may be suitable for study with ImmTOR-IL, with an initial focus on diseases of the liver.
    • Develop SEL-018 IgG Protease (Xork) for LOPD in Partnership with Astellas Gene Therapies. In January 2023, the Company announced an exclusive licensing and development agreement for IdeXork (Xork), a next-generation immunoglobulin G (IgG) protease, to be developed for use with AT845, Astellas Gene Therapies' investigational adeno-associated virus (AAV)-based treatment for Late-Onset Pompe disease (LOPD) in adults. Xork is designed to be differentiated by its low-cross reactivity to pre-existing antibodies in human serum, which the Company believes has the potential to expand access to life-changing gene therapies for more patients.
    • Advance Gene Therapy Programs through Potential Partnerships. Selecta will pause further development of its wholly-owned gene therapy programs, including the ongoing Phase 1/2 clinical trial of SEL-302, an AAV gene therapy combined with ImmTOR for the treatment of methylmalonic acidemia (MMA). The Company is currently assessing ways to support further development of these programs through potential partnerships.
    • Reduction in Force. The Company reduced its headcount by approximately 25% in order to align its workforce with its updated priorities. As a result of the reduction in force, the Company expects to incur a cash charge of approximately $1.0 million related to severance and benefit-related expenses.

    Dr. Brunn added, "The decision to enact these measures was extremely difficult, as we are losing many valued colleagues who helped advance Selecta to where it is today. I would like to express my sincere gratitude to all of these individuals."

    First Quarter 2023 Financial Results:

    Cash Position: Selecta had $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023, as compared to cash, cash equivalents, restricted cash, and marketable securities of $136.2 million as of December 31, 2022. Selecta believes that following the capital efficiencies expected to be realized through its strategic reprioritization, its available cash, cash equivalents, restricted cash, and marketable securities, as well as the next anticipated milestone payment related to SEL-212 development activities, will be sufficient to meet its operating requirements into the second half of 2025.

    Collaboration and License Revenue: Revenue for the first quarter of 2023 was $5.9 million, as compared to $34.0 million for the same period in 2022. Revenue was primarily driven by the shipment of clinical supply and the reimbursement of costs incurred for the Phase 3 DISSOLVE clinical program under the license agreement with Sobi.

    Research and Development Expenses: Research and development expenses for the first quarter of 2023 were $18.6 million, as compared to $17.7 million for the same period in 2022. The increase was primarily the result of expenses incurred for contract license and milestone payments and personnel expenses partially offset by a decrease in expenses incurred for the SEL-212 clinical program.

    General and Administrative Expenses: General and administrative expenses for the first quarter of 2023 were $5.7 million, as compared to $5.5 million for the same period in 2022. The increase was primarily the result of increased personnel expenses.

    Net (Loss) Income: For the first quarter of 2023, Selecta reported net loss of $21.7 million, or basic net loss per share of $(0.14). For the first quarter of 2022, Selecta reported net income of $28.8 million, or $0.23 per share.

    Conference Call and Webcast Reminder

    Selecta's management will host a conference call at 8:30 AM ET today to provide a corporate update and review the Company's first quarter 2023 financial results and strategic initiatives. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 6836582. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the Company's website, www.selectabio.com.

    About Selecta Biosciences, Inc.

    Selecta Biosciences Inc. (NASDAQ:SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body's natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

    Selecta Forward-Looking Statements

    Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (the "Company"), including without limitation, statements regarding the Company's expected cash runway; the Company's strategic prioritization of SEL-212 and its collaborations with Sobi and Astellas, the unique proprietary technology platform of the Company and its partners, the potential of ImmTOR to enable re-dosing of therapies and to mitigate immunogenicity, the potential of ImmTOR and the Company's product pipeline to treat chronic refractory gout, MMA, liver diseases, other autoimmune diseases, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the anticipated timing or the outcome of the FDA's review of the Company's regulatory filings, the Company's and its partners' ability to conduct its and their clinical trials and preclinical studies, the timing or making of any regulatory filings, the anticipated timing or outcome of selection of developmental product candidates, the ability of the Company to consummate any expected agreements and licenses, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, gout and autoimmune disease, the ability of the Company and its partners where applicable to develop gene therapy products using ImmTOR, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, the Company's plan to apply its ImmTOR technology platform to a range of biologics for rare and orphan genetic diseases, the potential of the ImmTOR technology platform generally, the Company's ability to grow and maintain its strategic partnerships, and enrollment in the Company's clinical trials and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "hypothesize," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company's ImmTOR technology, potential delays in enrollment of patients, undesirable side effects of the Company's product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the Company's inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company's recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company's common stock, risks related to geopolitical conflicts and pandemics and other important factors discussed in the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release, except as required by law.

    For Investors and Media:

    Blaine Davis

    Chief Financial Officer

    [email protected]

    Financial Tables

    Selecta Biosciences, Inc. and Subsidiaries

    Consolidated Balance Sheets

    (Amounts in thousands, except share data and par value)
     March 31, 2023 December 31, 2022
     (Unaudited)  
    Assets   
    Current assets:   
    Cash and cash equivalents$125,925  $106,438 
    Marketable securities —   28,164 
    Accounts receivable 6,839   6,596 
    Unbilled receivables 1,843   3,162 
    Prepaid expenses and other current assets 3,785   3,778 
    Total current assets 138,392   148,138 
    Non-current assets:   
    Property and equipment, net 2,765   2,794 
    Right-of-use asset, net 11,201   11,617 
    Long-term restricted cash 1,311   1,311 
    Investments 2,000   2,000 
    Other assets 24   26 
    Total assets$155,693  $165,886 
    Liabilities and stockholders' equity   
    Current liabilities:   
    Accounts payable$1,063  $316 
    Accrued expenses 9,347   14,084 
    Loan payable 10,218   8,476 
    Lease liability 1,671   1,608 
    Deferred revenue 4,232   593 
    Total current liabilities 26,531   25,077 
    Non-current liabilities:   
    Loan payable, net of current portion 16,228   17,786 
    Lease liability, net of current portion 9,617   10,055 
    Deferred revenue 5,519   — 
    Warrant liabilities 23,219   19,140 
    Total liabilities 81,114   72,058 
    Stockholders' equity:   
    Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2023 and December 31, 2022 —   — 
    Common stock, $0.0001 par value; 350,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 153,426,983 and 153,042,435 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 15   15 
    Additional paid-in capital 495,733   493,308 
    Accumulated deficit (416,600)  (394,937)
    Accumulated other comprehensive loss (4,569)  (4,558)
    Total stockholders' equity 74,579   93,828 
    Total liabilities and stockholders' equity$155,693  $165,886 



    Selecta Biosciences, Inc. and Subsidiaries

    Consolidated Statements of Operations and Comprehensive Income (Loss)

    (Amounts in thousands, except share and per share data)
     Three Months Ended
     March 31,
      2023   2022 
     (Unaudited)
      
    Collaboration and license revenue$5,938  $33,999 
    Operating expenses:   
    Research and development 18,624   17,689 
    General and administrative 5,695   5,537 
    Total operating expenses 24,319   23,226 
    Operating (loss) income (18,381)  10,773 
    Investment income 1,331   15 
    Foreign currency transaction, net 19   28 
    Interest expense (808)  (707)
    Change in fair value of warrant liabilities (4,079)  18,515 
    Other income, net 255   154 
    Net (loss) income$(21,663) $28,778 
        
    Other comprehensive income (loss):   
    Foreign currency translation adjustment (22)  (32)
    Unrealized gain on marketable securities 11   — 
    Total comprehensive income (loss)$(21,674) $28,746 
        
    Net (loss) income per share:   
    Basic$(0.14) $0.23 
    Diluted$(0.14) $0.08 
    Weighted average common shares outstanding:   
    Basic 153,345,554   124,232,799 
    Diluted 153,345,554   127,573,485 
        



    Primary Logo

    Get the next $SELB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SELB

    DatePrice TargetRatingAnalyst
    8/18/2023$1.00Outperform → Market Perform
    SVB Securities
    6/14/2022$6.00 → $5.00Buy
    Needham
    6/6/2022$7.00Outperform
    SVB Leerink
    11/1/2021$6.00 → $7.00Buy
    Needham
    More analyst ratings

    $SELB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)

      SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      2/14/24 12:38:55 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)

      SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      2/9/24 5:13:58 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Selecta Biosciences Inc.

      SC 13G - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      2/9/24 8:50:19 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Leadership Updates

    Live Leadership Updates

    See more
    • Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer

      WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, announced the appointment of Blaine Davis as Chief Financial Officer, effective today, November 28, 2022. "Blaine is a highly accomplished biopharmaceutical executive with proven financial and business development expertise," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. "We are preparing for a number of key potential milestones across our pipeline

      11/28/22 8:00:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Surface Oncology Appoints Carsten Brunn to Board of Directors

      CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company's board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe. "I am thrilled to welcome Carsten to the Surface Oncology board," said Rob Ross, M.D., chief executive officer at Surface. "Carsten is an accomplished biopharma executive with significant experience driving innovation and his counsel will be invaluable as we ad

      6/29/22 7:00:00 AM ET
      $SELB
      $SURF
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer

      WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Kevin Tan as chief financial officer. "Kevin's deep financial expertise and experience in the gene therapy and rare disease landscape makes him an ideal fit for Selecta's executive team," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "This is an exciting time for Selecta on the heels of our recent collaboration with Cyrus Biotechnology to unlock a new generation of inno

      9/20/21 8:00:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

      Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase 2a study in MG reported today; durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores observed approximately 10 months after last infusion Phase 2 study of Descartes-08 in systemic lupus erythematosus expected to initiate in 1H24 Clinical pipeline expanded following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate Approximately $118M pro forma cash and cash equivalents as of D

      1/8/24 7:10:00 AM ET
      $RNAC
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

      Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 observed to be well tolerated following administration in outpatient setting Publication is in peer review and available on the preprint server, medRxiv Topline data from Phase 2b placebo-controlled study continues to be expected in mid-2024 GAITHERSBURG, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC), ("the Company") a clinical-stage biotechnology company pioneering mRNA cell therap

      1/8/24 7:00:00 AM ET
      $RNAC
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Announces Merger with Cartesian Therapeutics

      – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen

      11/13/23 8:05:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Selecta Biosciences Inc.

      DEFA14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      2/14/24 5:27:24 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Selecta Biosciences Inc.

      DEF 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      2/14/24 4:42:00 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Selecta Biosciences Inc.

      PRE 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      1/31/24 4:30:29 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Financials

    Live finance-specific insights

    See more

    $SELB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Selecta Biosciences Announces Merger with Cartesian Therapeutics

      – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen

      11/13/23 8:05:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics

      – Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its cli

      8/17/23 7:00:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

      - Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout; BLA filing expected in 1H 2024 - - Selecta to host conference call today at 8:30 AM ET - WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first quarter

      5/4/23 7:30:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences downgraded by SVB Securities with a new price target

      SVB Securities downgraded Selecta Biosciences from Outperform to Market Perform and set a new price target of $1.00

      8/18/23 7:37:44 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Selecta Biosciences with a new price target

      Needham reiterated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $5.00 from $6.00 previously

      6/14/22 7:48:06 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Selecta Biosciences with a new price target

      SVB Leerink initiated coverage of Selecta Biosciences with a rating of Outperform and set a new price target of $7.00

      6/6/22 7:48:05 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Singer Michael was granted 178,000 units of Common Stock, increasing direct ownership by 162% to 288,123 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:12:27 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Davis Blaine was granted 2,424,000 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:29 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jewell Christopher M was granted 778,200 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:06 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care